TABLE 2.

The efficacy of different BB therapies on reducing the occurrence of CEs (syncope, SCD, ACA) in patients with LQT1 and LQT2 by the network meta-analysis using HR and 95% CrIs.

LQT1
Cardiac events	Atenolol	1.4 (0.66–2.7)	1.4 (0.56–3.0)	0.86 (0.41–1.8)
	0.73 (0.37–1.5)	Propranolol	1.0 (0.48–2.1)	0.63 (0.32–1.3)
	0.71 (0.33–1.7)	0.98 (0.49–2.1)	Metoprolol	0.61 (0.3–1.4)
	1.2 (0.56–2.4)	1.6 (0.76–3.1)	1.6 (0.7–3.3)	nadolol
LQT2
Cardiac events	Atenolol	0.98 (0.63–1.4)	0.99 (0.64–1.5)	0.35 (0.22–0.55)
	1.0 (0.7–1.6)	Propranolol	1.0 (0.66–1.6)	0.36 (0.23–0.58)
	1.0 (0.65–1.6)	0.98 (0.62–1.5)	Metoprolol	0.35 (0.21–0.57)
	2.9 (1.8–4.6)	2.8 (1.7–4.4)	2.9 (1.7–4.7)	nadolol